AxoGen, Inc. (AXGN) is a $345M maker of surgical solutions for peripheral nerve injuries.
Below is a deeper summary of the company and its financial metrics.
AXGN’s stock is trading at 5.8X EV/Sales for FY17 and 4.3X FY18. AXGN hit $41M in revenues in 2016, up from $10.9M in 2013. It’s forecasting $77M for 2018 and also expecting to be near profitability in 2018. Data sourced from YahooFinance.
Nerve injuries impact 20M Americans and results in $150B in annual health-care dollars spent. AXGN is exclusively focused on peripheral nerve repair and protection solutions with a product portfolio addressing over 900,000 procedures, and an estimated $1.8B market opportunity. Roth Capital started shares a Buy on 3-6 with a $14.50 target, and Lake Street upgraded to Buy in November with an $11 target after AXGN unveiled a new product for adhesion prevention called Avive and two other pipeline development programs in breast reconstruction and lower limb iatrogenic nerve injury.
On the chart shares have a strong uptrend since early 2016 with a recent breakout above $9.15 out of a bull flag, and currently consolidating below the $11 level. Shares should target $15 on the next trend move higher. Institutional ownership jumped 22.5% in Q4 13F filings with notable buyers such as Gilder Gagnon Howe and Cortina Asset Management. Deerfield Mgmt. is the third largest holder of the stock. Back in October AXGN saw insider buys with the CEO, CFO, VP, VP of Marketing, and Director each buying stock at $7.50/share for a total of around $245,000.
You can catch more of my research and options trading ideas over at OptionsHawk.  Thanks for reading and have a great week!
ALSO READ: Â Amazon Stock Chart Update: Defying Gravity
Twitter:Â @OptionsHawk
The author does not have a position in mentioned securities at the time of publication. Â Any opinions expressed herein are solely those of the author, and do not in any way represent the views or opinions of any other person or entity.
